Opioid Analgesic Risk Management Should Not Inhibit Access, Cmte. Says
Executive Summary
Risk management plans for opioid analgesics should be modified if it appears the plan inhibits access for the appropriate patient population, FDA's Anesthetic & Life Support Drugs Advisory Committee said
You may also be interested in...
Ligand Avinza Once-Daily Dosing Will Be Core Promo Message For Elan Opioid
Ligand will focus on Avinza once-daily dosing as the opioid's primary marketing message following the March 20 approval of the extended-release morphine drug licensed from Elan
Ligand Avinza Once-Daily Dosing Will Be Core Promo Message For Elan Opioid
Ligand will focus on Avinza once-daily dosing as the opioid's primary marketing message following the March 20 approval of the extended-release morphine drug licensed from Elan
Homogeneous Opioid Trial Populations Could Simplify, Improve Data – Cmte
Limiting opioid trial populations to specific pain syndromes could improve safety and efficacy evaluations of the analgesics, FDA's Anesthetic & Life Support Drugs Advisory Committee suggested